Pertuzumab

Reimbursement reviews of drugs later in the life cycle include a comprehensive assessment of clinical value, unmet clinical need, distinct social and ethical considerations, economic considerations, and impacts on the health systems. The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial drug plans and cancer agencies. This review assesses pertuzumab, 840 mg loading dose and 420 mg maintenance dose, IV infusion. Indication under consideration for reimbursement: Pertuzumab in combination with trastuzumab and chemotherapy for early-stage HER2-positive breast cancer in the neoadjuvant setting.